Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.

Trial Details

NCT ID
NCT07509008
Phase
PHASE1 / PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • TGFBR2 KO CAR27/IL-15 NK cells
  • Rimiducid (AP1903)
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Subjects must be 18 years or older. Because no dosing or adverse event data are currently available on the use of CAR NK cells in combination with …
  • Subjects must be willing and able to provide informed consent.
  • Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • A female participant is eligible to participate if at least one of the following conditions applies:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →